Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients


Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.

Aim(s): To compare biodistribution, lesion targeting and tumor uptake of Al18F-OC to 68Ga-DOTATATE in neuroendocrine tumor (NET) patients.

Materials and methods: Six NET patients (5M/1F; age 48-74 y) underwent a PET/CT scan at 1, 2 and 3 hours post injection (PI) of 4 MBq/kg Al18F-OC. All patients had a 68Ga-DOTATATE PET prior to the study scan (interval: 14-71 days). A lesion-by-lesion analysis was performed and the detection ratio (fraction of lesions detected; DR) was determined. Biodistribution and tumor uptake were compared by measuring mean standardized uptake values (SUVmean) in normal organs and SUVmax in tumor lesions. Also, tumor-to-background ratios (TBR) for liver, bone and lymph node lesions were calculated, using normal liver, bone and gluteal muscle as background, respectively.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K,

Keywords: neuroendocrine tumors, PET, Al18F-NOTA-octreotide, 68Ga-DOTATATE, somatostatin receptor imaging,

To read the full abstract, please log into your ENETS Member account.